Individualized treatment of chronic hepatitis B

摘要：

Revolutionary，changes have been made in the treatment of chronic hepatitis B(CHB)in the past decade.InChina,there are six approved agents，including two forms ofinterferon(conventional and pegylated)andfour oral nucleoside／nucleotide analogues(1amivudine，adefovir,entecavir and telbivudine)．The phase III registrationtrial of tenofovir disoproxil fumarate is ongoing and will be anticipated to come into the market in China within 2years．The availability of these multiple treatment options has led to expansion of treatment indications．However,the indefinite treatment duration with some therapies，the high costs ofHBV medications，the side effects associatedwith some treatments and the risks ofdrug resistance during long-term oral antiviral drugs treatment necessitatecareful balancing the risk and benefit prior to initiating treatment．

作者: JianSun Rong Fan Jinlin Hou

作者单位: Department of Infectious Diseases ＆Hepatology Unit,Nanfang Hospital,Southern Medical University,Guan Department of Infectious Diseases ＆ Hepatology Unit,Nanfang Hospital,Southern Medical University,Gua

会议类型: 国内会议

会议名称: 第八届全国肝脏疾病临床学术大会暨第四届中国-印度尼西亚肝病峰会

会议地点: 南宁

会议语种:英文

页码: 333-335

在线出版日期: 2012-06-07（万方平台首次上网日期，不代表论文的发表时间）